We used such an approach to improve complete response rates by nearly 6-fold in HER2pos/ERpos early breast cancer by combining a brief course of anti-estrogen therapy with anti-HER-2 Th1-polarizing vaccination [9]. This evidence concerns the gene ERBB2 and breast cancer.